Activity of rat UGT1A1 towards benzo[a]pyrene phenols and dihydrodiols

被引:3
作者
Webb, L [1 ]
Miles, K [1 ]
Kessler, F [1 ]
Ritter, JK [1 ]
机构
[1] Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA
关键词
UDP-glucuronosyltransferase; benzo[a]pyrene; glucuronidation; environmental carcinogenesis;
D O I
10.1016/j.etap.2005.07.018
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Four UDP-glucuronosyltransferases from the rat UGT1A family were tested for activity towards benzo[a]pyrene pyenols and dihydrodiols. UGTIA1 and UGTI1A7 were found to be broadly active towards BaP metabolites. Antisera recognizing rat UGT1A1 and UGT1A7 were used to assess UGT levels in relation to UGT activity towards benzo[a]pyrene-7.8-dihydrodiol (BPD). The rank BPD UGT activities were liver=intestine kidney, whereas UGT1A1 was highest in liver and UGT1A7 was highest in intestine. Phenobarbital, an inducer of hepatic UGT1A1, only slightly increased BPD UGT activity, whereas UGT1A7 inducers more potently increased the activity. Inhibition studies using the differential UGTIAI inhibitor, bilirubin, suggest that UGT1A1 is not a major contributor to the constitutive BPD glucuronidating activity of control rat liver microsomes. These data suggest that multiple UGT1A enzymes contribute to glucuronidation of BPD and other BaP metabolites, and that their relative contributions depend on tissue- and environmental-specific factors. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:224 / 230
页数:7
相关论文
共 50 条
  • [21] Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
    Maeda, Hiromichi
    Hazama, Shoichi
    Shavkat, Abdiev
    Okamoto, Ken
    Oba, Koji
    Sakamoto, Junichi
    Takahashi, Kenichi
    Oka, Masaki
    Nakamura, Daisuke
    Tsunedomi, Ryouichi
    Okayama, Naoko
    Mishima, Hideyuki
    Kobayashi, Michiya
    MOLECULAR DIAGNOSIS & THERAPY, 2014, 18 (03) : 333 - 342
  • [22] Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients
    Han, Fei-fei
    Guo, Chang-long
    Yu, Dan
    Zhu, Jin
    Gong, Li-li
    Li, Guang-run
    Lv, Ya-li
    Liu, He
    An, Guang-yu
    Liu, Li-hong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (04) : 779 - 788
  • [23] Evidence for phosphorylation requirement for human bilirubin UDP-glucuronosyltransferase (UGT1A1) activity
    Basu, NK
    Kole, L
    Owens, IS
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 303 (01) : 98 - 104
  • [24] UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
    Takano, Masashi
    Sugiyama, Toru
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2017, 10 : 61 - 68
  • [25] Screening of patients with Gilbert's Syndrome from South India identifies UGT1A1*28 as the most predominant mutation in UGT1A1 gene
    Iyer, Dhanya Ramakrishna
    Parani, Madasamy
    RESEARCH JOURNAL OF BIOTECHNOLOGY, 2018, 13 (04): : 37 - 40
  • [26] Glucuronidation of piceatannol by human liver microsomes: major role of UGT1A1, UGT1A8 and UGT1A10
    Miksits, Michaela
    Maier-Salamon, Alexandra
    Thanh Phuong Nha Vo
    Sulyok, Michael
    Schuhmacher, Rainer
    Szekeres, Thomas
    Jaeger, Walter
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2010, 62 (01) : 47 - 54
  • [27] Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients
    Jada, Srinivasa Rao
    Lim, Robert
    Wong, Chiung Ing
    Shu, Xiaochen
    Lee, Soo Chin
    Zhou, Qingyu
    Goh, Boon Cher
    Chowbay, Balram
    CANCER SCIENCE, 2007, 98 (09): : 1461 - 1467
  • [28] Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity
    Takekuma, Yoh
    Takenaka, Toru
    Yamazaki, Koujiro
    Ueno, Kazuyuki
    Sugawara, Mitsuru
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (11) : 2146 - 2153
  • [29] Genetic polymorphism in the conjugating enzyme UGT1A1 and the risk of head and neck cancer
    Lacko, Martin
    Roelofs, Hennie M. J.
    Morsche, Rene H. M. Te
    Voogd, Adri C.
    Ophuis, Michel B. Oude
    Peters, Wilbert H. M.
    Manni, Johannes J.
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) : 2815 - 2821
  • [30] UGT1A1 and UGT1A9 Are Responsible for Phase II Metabolism of Tectorigenin and Irigenin In Vitro
    Li, Ji
    Xu, Zhangyao
    Gu, Jifeng
    MOLECULES, 2022, 27 (13):